Last reviewed · How we verify
R-DA-EPOCH-21
R-DA-EPOCH-21 is a chemotherapy regimen that combines rituximab, doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone.
R-DA-EPOCH-21 is a chemotherapy regimen that combines rituximab, doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone. Used for Diffuse large B-cell lymphoma.
At a glance
| Generic name | R-DA-EPOCH-21 |
|---|---|
| Also known as | R-DA-EPOCH |
| Sponsor | National Research Center for Hematology, Russia |
| Drug class | chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This regimen is designed to target and kill rapidly dividing cancer cells. The combination of drugs works synergistically to induce apoptosis and inhibit cell proliferation.
Approved indications
- Diffuse large B-cell lymphoma
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Fatigue
Key clinical trials
- R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL (PHASE3)
- R-BL-M-04 Versus R-(DA)-EPOCH and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit (HGBL DH) and High-Grade B-cell Lymphoma Not Otherwise Specified (HGBL NOS) (PHASE3)
- R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |